Equities Analysts Offer Predictions for DBVT FY2026 Earnings

Key Points

• HC Wainwright lowered its FY2026 EPS forecast for DBV Technologies to a loss of $1.90 from $1.75, while maintaining a Buy rating. The firm projects losses in FY2027 before forecasting earnings of $4.60 in FY2029 and $8.00 in FY2030.
• DBV Technologies reported a third-quarter loss of $0.70 per share, missing the $0.29 consensus estimate, although revenue of $1.60 million exceeded expectations. The company continues to face deeply negative profitability metrics and heightened liquidity and financing risks.
• Analyst sentiment remains broadly positive, with five Buy ratings and one Sell rating producing a Moderate Buy consensus and an average price target of $45.25. However, several firms recently reduced their price targets, while the stock opened at $9.49, near its 52-week low.

DBV Technologies S.A. (NASDAQ:DBVT - Free Report) - Investment analysts at HC Wainwright cut their FY2026 earnings estimates for shares of DBV Technologies in a research report issued on Thursday, October 29th. HC Wainwright analyst A. Fein now forecasts that the company will post earnings per share of ($1.90) for the year, down from their previous forecast of ($1.75). HC Wainwright has a "Buy" rating on the stock. The consensus estimate for DBV Technologies' current full-year earnings is ($2.22) per share. HC Wainwright also issued estimates for DBV Technologies' Q4 2026 earnings at ($0.75) EPS, FY2027 earnings at ($1.25) EPS, FY2029 earnings at $4.60 EPS and FY2030 earnings at $8.00 EPS.

DBV Technologies (NASDAQ:DBVT - Get Free Report) last released its earnings results on Wednesday, October 28th. The company reported ($0.70) earnings per share for the quarter, missing analysts' consensus estimates of ($0.29) by ($0.41). DBV Technologies had a negative net margin of 5,392.17% and a negative return on equity of 120.95%. The business had revenue of $1.60 million during the quarter, compared to the consensus estimate of $0.56 million.

A number of other research firms have also weighed in on DBVT. Weiss Ratings reissued a "sell (e+)" rating on shares of DBV Technologies in a research report on Thursday, October 15th. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of DBV Technologies in a report on Thursday, September 10th. Citizens Jmp dropped their price objective on shares of DBV Technologies from $55.00 to $47.00 and set a "market outperform" rating for the company in a research note on Thursday. Citigroup reaffirmed a "market outperform" rating on shares of DBV Technologies in a report on Thursday. Finally, Guggenheim lowered their price target on shares of DBV Technologies from $51.00 to $46.00 and set a "buy" rating on the stock in a report on Friday. Five analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, DBV Technologies presently has a consensus rating of "Moderate Buy" and an average price target of $45.25.

DBV Technologies Price Performance

Shares of NASDAQ:DBVT opened at $9.49 on Monday. DBV Technologies has a 52 week low of $8.63 and a 52 week high of $26.18. The stock has a market cap of $596.73 million, a PE ratio of -3.15 and a beta of -0.84. The company's fifty day moving average is $11.53 and its 200 day moving average is $16.93.

Institutional Trading of DBV Technologies

Large investors have recently added to or reduced their stakes in the company. China Universal Asset Management Co. Ltd. raised its stake in shares of DBV Technologies by 170.0% in the third quarter. China Universal Asset Management Co. Ltd. now owns 21,600 shares of the company's stock worth $249,000 after purchasing an additional 13,600 shares during the last quarter. Vontobel Holding Ltd. purchased a new position in shares of DBV Technologies in the third quarter valued at $144,000. Perceptive Advisors LLC acquired a new stake in DBV Technologies in the 1st quarter worth about $20,146,000. Vivo Capital LLC lifted its stake in shares of DBV Technologies by 8.4% during the first quarter. Vivo Capital LLC now owns 2,667,569 shares of the company's stock worth $55,726,000 after purchasing an additional 205,943 shares in the last quarter. Finally, ADAR1 Capital Management LLC bought a new stake in shares of DBV Technologies in the 1st quarter worth about $21,159,000. Institutional investors own 71.74% of the company's stock.

DBV Technologies News Summary

Here are the key news stories impacting DBV Technologies this week:

• Positive Sentiment: DBV submitted a Biologics License Application to the FDA for the VIASKIN Peanut Patch in children ages 4–7 and requested Priority Review. The company also said it is accelerating commercial preparations, supporting the potential value of the product if approved. DBV Technologies Reports Third Quarter 2026 Financial Results and Business Update
• Positive Sentiment: HC Wainwright raised its FY2028 earnings estimate to $1.25 per share from $1.15 and maintained a Buy rating, reflecting greater confidence in the company’s longer-term commercial outlook.
• Positive Sentiment: Guggenheim maintained a Buy rating and lowered its price target to $46 from $51. Despite the reduction, the target implies substantial upside from recent trading levels.
• Neutral Sentiment: DBV reported $165.7 million in cash and cash equivalents as of September 30, which management said should fund operations into the third quarter of 2027. However, the company remains dependent on future execution and regulatory progress.
• Negative Sentiment: Third-quarter EPS was a loss of $0.70, substantially worse than the consensus loss estimate of $0.26. Revenue of $1.60 million exceeded the $0.56 million estimate, but the company continues to report deeply negative profitability metrics. DBV Technologies Report Wider Q3 Loss, Advances Peanut Allergy Patch Toward Potential Launch
• Negative Sentiment: DBV disclosed heightened going-concern risk as liquidity constraints increase the possibility of dilutive financing. A new equity raise could pressure existing shareholders and likely contributes to the stock’s weakness. DBV Technologies Faces Heightened Going-Concern Risk
• Negative Sentiment: Citizens lowered its price target to $47 from $55 while maintaining a Market Outperform rating, citing third-quarter manufacturing risk. The target reduction reinforces concerns about execution ahead of a potential launch.

About DBV Technologies

DBV Technologies SA NASDAQ: DBVT is a clinical-stage biopharmaceutical company focused on developing treatments for food allergies and other immune-mediated conditions. The company's approach is based on epicutaneous immunotherapy, which is designed to deliver small amounts of an allergen through the skin to help desensitize the immune system.

DBV Technologies' lead product candidate is Viaskin Peanut, an investigational patch intended to treat peanut allergy, particularly in children.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.